Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Flunisolide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 8/20 | 1.00 |
| ▸ | PGR | P06401 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.70 |
| ▸ | AR | P10275 | 4/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.53 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flunisolide SCHEMBL19681909 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRNR3C1LMNAABCB11 | |
| Flunisolide SCHEMBL13602384 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRNR3C1LMNAABCB11 | |
| Flunisolide SCHEMBL13026142 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRNR3C1LMNAABCB11 | |
| Flunisolide SCHEMBL8810954 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRNR3C1LMNAABCB11 | |
| Flunisolide SCHEMBL30994800 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRNR3C1LMNAABCB11 | |
| Flunisolide SCHEMBL5493687 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRNR3C1LMNAABCB11 | |
| Flunisolide SCHEMBL5187487 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRNR3C1LMNAABCB11 | |
| Flunisolide SCHEMBL66051 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRNR3C1LMNAABCB11 | |
| Flunisolide SCHEMBL13662143 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRNR3C1LMNAABCB11 | |
| Flunisolide SCHEMBL22527648 | 0.99 | CYP3A4 (0.98) | CYP3A4PGRNR3C1LMNAABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 45891 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6423298-B1 | — | — | None | — | — | US | claimed |
| US-20260139030-A1 | CHIMERIC PROTEINS FOR TREATING CUTANEOUS INFLAMMATION | SHATTUCK LABS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137656-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137657-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS | SPARROW PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| US-20260130899-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2026-05-14 | — | — | US | claimed |
| EP-4739294-A1 | AN INHALABLE FORMULATION OF FLUTICASONE PROPIONATE AND ALBUTEROL SULFATE FOR THE TREATMENT OF ASTHMA | Norton (Waterford) Limited (IE) | 2026-05-13 | — | — | EP | claimed |
| EP-4739295-A1 | AN INHALABLE FORMULATION OF FLUTICASONE PROPIONATE AND ALBUTEROL SULFATE FOR THE TREATMENT OF ASTHMA | Norton (Waterford) Limited (IE) | 2026-05-13 | — | — | EP | claimed |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-0239798-A1 | New pharmaceutical compositions for inhalation | CHIESI FARMACEUTICI S.p.A. (IT) | 1987-10-07 | — | — | EP | claimed |
| WO-1987005213-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR INHALATION | CHIESI FARMACEUTICI S.P.A. (IT) | 1987-09-11 | — | — | WO | claimed |
| EP-0173478-A1 | Treatment of skin disorders | SCOTIA HOLDINGS PLC (GB) | 1986-03-05 | — | — | EP | claimed |
| EP-0170642-A2 | Liposomes containing steroid esters | Aktiebolaget Draco (SE) | 1986-02-05 | — | — | EP | claimed |
| US-4478818-A | Ocular preparation housing steroid in two different therapeutic forms | ALZA CORPORATION (US) | 1984-10-23 | — | — | US | claimed |
| US-4427670-A | CONTAINING CORTICOSTEROID, PHOSPHATIDE, AND BUTYLHYDROXYANISOLE, OR BUTYLHYDROXYTOLUENE | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1984-01-24 | — | — | US | claimed |
| US-4376767-A | ANTIBIOTICS AND PHARMACEUTICALS | MERCK & CO., INC. (US) | 1983-03-15 | — | — | US | claimed |
| EP-0055870-A1 | Pyridylmethyl esters of selected bio-affecting carboxylic acids, process for preparing and pharmaceutical composition comprising the same | MERCK & CO. INC. (US) | 1982-07-14 | — | — | EP | claimed |
| EP-0051278-A1 | Soft tertiary amine esters of bio-affecting carboxylic acids, processes for preparing and a pharmaceutical composition containing the same | MERCK & CO. INC. (US) | 1982-05-12 | — | — | EP | claimed |
| US-4273710-A | CRYSTALLIZATION FROM BUTANOL OR PROPANOL | SYNTEX CORPORATION (US) | 1981-06-16 | — | — | US | claimed |